Melanoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Incyte Corporation, Merck Sharp & Dohme LLC, Daiichi Sankyo Co., Ltd., Amgen, Bristol-Myers Squibb, Medarex, Ono Pharmaceutical Co. Ltd, ModernaTX, Inc

Melanoma emerging therapies such as AMTAGVI (lifileucel), OPDIVO (nivolumab), Fianlimab + Cemiplimab, IO102-IO103 + KEYTRUDA, and others are expected to boost the Melanoma Market in the upcoming years.

DelveInsight has launched a new report on "Melanoma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Melanoma, historical and forecasted epidemiology as well as the Melanoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download our free melanoma market sample report @ https://www.delveinsight.com/report-store/melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Melanoma Market Report:

In 2023, the United States held the largest market share for melanoma among the seven major markets (7MM), with expectations of continued growth throughout the forecast period.
Among the seven major markets (7MM), the United States had the highest number of invasive melanoma cases, estimated at around 100,000 in 2023.
Melanoma is slightly more prevalent in men than in women, with men accounting for approximately 60% of cases in the U.S.
Currently, a wide range of melanoma treatments is available, including surgical procedures (such as hysterectomy), chemotherapy, radiation therapy, and targeted drug therapies focusing on PD-1 and LAG-3.
In April 2024, Obsidian Therapeutics shared an update on its Phase I first-in-human trial of OBX-115, a tumor-infiltrating lymphocyte (TIL) cell therapy for patients with advanced or metastatic melanoma. The update, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, included 25-week median follow-up safety data along with newly detailed efficacy results.
Additionally, in April 2024, Iovance Biotherapeutics announced that clinical data on lifileucel in combination with pembrolizumab for frontline advanced melanoma, along with translational findings, will be showcased at the 2024 ASCO Annual Meeting.
At ASCO 2024, Moderna presented data comparing pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with a placebo for the adjuvant treatment of high-risk stage II-IV melanoma. Additionally, a three-year update from the mRNA-4157-P201 (KEYNOTE-942) trial examined the combination of mRNA-4157 (V940) and pembrolizumab in resected melanoma.
Following FDA approval, AMTAGVI became the first T-cell therapy authorized for a solid tumor cancer and the first treatment option for advanced melanoma after anti-PD-1 and targeted therapy. Meanwhile, OPDUALAG, approved by the FDA in 2022 for unresectable or metastatic melanoma, is currently being evaluated for additional melanoma indications.
In 2023, the FDA granted Orphan Drug Designation to Linnaeus Therapeutics' LNS8801 for treating metastatic cutaneous melanoma.
The melanoma treatment pipeline appears robust, with key players including IO Biotech, Regeneron Pharmaceuticals, Iovance Biotherapeutics, Highlight Therapeutics, Linnaeus Therapeutics, Ultimovacs, BioNTech, and others.
Overall, the melanoma treatment landscape is expected to witness significant growth from 2024 to 2034. The future looks promising for melanoma patients, with targeted therapies and biomarker-driven treatments offering potential improvements in outcomes, both as monotherapies and combination approaches.
Key Melanoma companies such as Incyte Corporation, Merck Sharp & Dohme LLC, Daiichi Sankyo Co., Ltd., Amgen, Bristol-Myers Squibb, Medarex, Ono Pharmaceutical Co. Ltd, ModernaTX, Inc., Nektar Therapeutics, and others are evaluating new drugs for Melanoma to improve the treatment landscape.
Promising Melanoma pipeline therapies in various stages of development include AMTAGVI (lifileucel), OPDIVO (nivolumab), Fianlimab + Cemiplimab, IO102-IO103 + KEYTRUDA, and others.
Key benefits of the Melanoma market report:
Melanoma market report covers a descriptive overview and comprehensive insight of the Melanoma Epidemiology and Melanoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Melanoma market report provides insights on the current and emerging therapies.
Melanoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Melanoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Melanoma market.

Got queries? Click here to know more about the Melanoma Market Landscape https://www.delveinsight.com/sample-request/melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Melanoma Overview
Melanoma is a prevalent form of skin cancer that originates from melanin-producing cells in the outer skin layer (epidermis) or similar cells found in moles (nevi). This cancer can extend into deeper skin layers, with microscopic roots potentially spreading (metastasizing) to vital organs, leading to new tumor growths. Melanoma is generally categorized into three types: cutaneous, mucosal, and ocular.
The exact cause of malignant melanoma remains unclear, though excessive sun exposure, especially before puberty, and residing in sun-intense regions (such as tropical climates) increase the risk. A genetic mutation in the CDK4 gene has been linked to a heightened risk of familial malignant melanoma.
Among the three types, cutaneous melanoma is the most common and is typically classified as either primary or metastatic. Primary melanoma is further subdivided into:
a) Melanoma in situ, where abnormal melanocytes are confined to the epidermis.
b) Invasive melanoma, which penetrates the dermis.
Invasive melanoma has historically been classified into four major histological subtypes based on clinical and pathological characteristics: superficial spreading melanoma, lentigo melanoma, nodular melanoma, and acral melanoma.
Melanoma Market Outlook

Melanoma treatment primarily aims to extend survival, eradicate cancer, halt or reduce metastatic tumor growth, and manage symptomatic or high-risk disease sites to improve patient comfort. The current treatment landscape includes immunotherapy, targeted therapy, intralesional therapy, chemotherapy, and radiation therapy, with surgery also being a viable option in certain cases.

In February 2024, the FDA approved AMTAGVI, the first tumor-infiltrating lymphocyte (TIL) therapy, developed by Iovance Biotherapeutics. Other approved treatments include KEYTRUDA (Merck) and the combination of TECENTRIQ + COTELLIC + ZELBORAF (Genentech).

Despite the availability of multiple treatment options, ongoing research continues to explore innovative therapeutic approaches. Leveraging advancements in melanoma research, scientists are refining treatment combinations and strategies to improve patient outcomes. The goal is to transform advanced melanoma from a life-threatening disease into a chronic, manageable, or potentially curable condition.

Leading companies such as Merck, Binhui Biopharmaceutical, Bristol-Myers Squibb, and Iovance Biotherapeutics are actively evaluating their key drug candidates at various stages of clinical development.

Request for a sample report @ https://www.delveinsight.com/report-store/melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Melanoma Marketed Drugs:

AMTAGVI (lifileucel): Iovance Biotherapeutics
OPDIVO (nivolumab): Bristol-Myers Squibb

Melanoma Emerging Drugs:

Fianlimab + Cemiplimab: Regeneron Pharmaceuticals
IO102-IO103 + KEYTRUDA: IO Biotech

Explore more about the therapies emerging in the melanoma market @ https://www.delveinsight.com/sample-request/melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Melanoma Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Melanoma Companies: Incyte Corporation, Merck Sharp & Dohme LLC, Daiichi Sankyo Co., Ltd., Amgen, Bristol-Myers Squibb, Medarex, Ono Pharmaceutical Co. Ltd, ModernaTX, Inc., Nektar Therapeutics, and others
Key Melanoma Therapies: AMTAGVI (lifileucel), OPDIVO (nivolumab), Fianlimab + Cemiplimab, IO102-IO103 + KEYTRUDA, and others
Melanoma Therapeutic Assessment: Melanoma current marketed and Melanoma emerging therapies
Melanoma Market Dynamics: Melanoma market drivers and Melanoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Melanoma Unmet Needs, KOL's views, Analyst's views, Melanoma Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Melanoma Patient Share (%) Overview at a Glance
5. Melanoma Market Overview at a Glance
6. Melanoma Disease Background and Overview
7. Melanoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Melanoma
9. Melanoma Current Treatment and Medical Practices
10. Unmet Needs
11. Melanoma Emerging Therapies
12. Melanoma Market Outlook
13. Country-Wise Melanoma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Melanoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Melanoma Market Outlook 2034 https://www.delveinsight.com/report-store/melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Melanoma Pipeline Insights, DelveInsight

"Melanoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Melanoma market. A detailed picture of the Melanoma pipeline landscape is provided, which includes the disease overview and Melanoma treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.